Clinical and pharmacokinetic/dynamic outcomes of prolonged infusions of beta-lactam antimicrobials: An overview of systematic reviews

Pierre Thabet, Anchal Joshi, Erika MacDonald, Brian Hutton, Wei Cheng, Adrienne Stevens, Salmaan Kanji

Abstract

Objective
This overview of reviews aims to map and compare of objectives, methods, and findings of existing systematic reviews to develop a greater understanding of the information available about prolonged beta-lactam infusions in hospitalized patients with infection.

Design
Overview of systematic reviews.

Data sources
Medline, Embase, PROSPERO and the Cochrane Library were systematically searched from January, 1990 to June, 2019 using a peer reviewed search strategy. Grey literature was also searched for relevant reviews.

Eligibility criteria for selecting reviews
Systematic reviews were sought that compared two or more infusion strategies for intravenous beta-lactam antimicrobials and report clinical cure or mortality. Populations of included reviews were restricted to hospitalized patients with infection, without restrictions on age, infection type, or disease.

Data extraction and analysis
Abstract screening, data extraction, quality and risk of bias assessment were conducted by two independent reviewers. Overlap between reviews was assessed using a modified corrected covered area. Overview findings are reported in accordance with Cochrane’s recommendation for overview conduct. Clinical outcomes extracted included survival, clinical cure, treatment failure, microbiological cure, length of stay, adverse events, cost, and emergence of resistance.
Results
The search strategy identified 3327 unique citations from which 21 eligible reviews were included. Reviews varied by population, intervention and outcomes studied. Between reviews, overlap of primary studies was generally high, methodologic quality generally low and risk of bias variable. Nine of 14 reviews that quantitatively evaluated mortality and clinical cure identified a benefit with prolonged infusions of beta lactams when compared with intermittent infusions. Evidence of mortality and clinical cure benefit was greater among critically ill patients when compared to less sick patients and lower in randomized controlled trials when compared with observational studies.

Conclusions
Findings from our review demonstrate a consistent and reproducible lack of harm with prolonged infusions of beta-lactam antibiotics with variability in effect size and significance of benefits. Despite 21 systematic reviews addressing prolonged infusions of beta-lactams, this overview supports the continued need for a definitive systematic review given variability in populations, interventions and outcomes in the current systematic reviews. Subsequent systematic reviews should have more rigorous and transparent methods, only include RCTs and evaluate the proposed benefits found in various subgroup-analyses—i.e. high risk of mortality.

Trial registration
Prospero registry, CRD42019117118.

Introduction
Despite antimicrobial therapy, many patients experience negative infection related outcomes. This is particularly true of patients with sepsis and the critically ill [1, 2]. Advancements in supportive care and bundled care initiatives such as the Surviving Sepsis Campaign have minimal impact on sepsis-associated morbidity and mortality [3, 4]. Meanwhile, antimicrobial resistance has increased at a staggering pace. Current guidelines for antimicrobial use focus on what is administered and when it is administered without considering how it is administered [5]. The method of antibiotic administration, particularly for beta-lactam antibiotics, can have a substantial impact on patient outcomes [6]. Accordingly, there is an urgent need to establish the optimal method of beta-lactam antimicrobial administration in specific patient populations.

The greatest predictor of antimicrobial-related treatment failure is inadequate dosing that results in sub-therapeutic serum drug concentrations [7]. Up to 50% of septic patients are inadequately dosed due to extremely variable pharmacokinetics (PK), such as drug clearance, metabolism and volume of distribution differences [8–10]. Typically, pharmacodynamic (PD) targets from 40–70% time above the MIC ($\text{FT}_{\text{MIC}}$) are associated with improved outcomes from animal and human studies for beta-lactam antimicrobials depending on the sub-class of beta-lactam (i.e., penicillins, cephalosporins and carbapenems) and the organism causing the infection [11, 12]. Growing concern as to generalizability of this target has been expressed, and there is a mounting evidence supporting a target of 100% time above the MIC for critically ill patients and those with life threatening infections with resistant organisms [13, 14]. PD models
support increasing the infusion time of beta-lactams to improve the probability of attaining adequate serum antimicrobial concentrations, and clinical trials have demonstrated that greater survival can be achieved in critically ill patients receiving prolonged infusions of beta-lactam antimicrobials [15, 16]. Despite this, most beta-lactam antimicrobials are administered as intermittent boluses, with unpredictable PK contributing to subtherapeutic serum concentrations and antimicrobial-related treatment failure.

While antimicrobial stewardship strategies that encourage appropriate use of antimicrobials have had some success in slowing the development of resistance, a greater understanding of methods to optimize the use of antimicrobials is necessary [17]. Altering the method of administration of beta-lactams to achieve optimal pharmacodynamics represents a low-cost, low-risk change in practice that can slow the development of resistance and improve the outcomes of patients with sepsis and septic shock [18–21].

Various methods of administration of intravenous beta-lactam antimicrobials exist that are potentially associated with different PD target attainment rates and patient outcomes. Intermittent doses are generally given over 30 or 60 minutes, one to six times per day depending on the drug. Extended infusions are administered over 3–4 hours per dose, while for continuous infusions, the entire daily dose is infused over 24 hours.

The literature evaluating prolonged infusion of beta-lactam antibiotics has been polarizing due to both positive and equivocal studies, of which there are over 60. Systematic reviews exist that evaluate the clinical impact of antimicrobial administration method, but the messaging is again inconsistent due to variable studies, outcomes and quality of the reviews [22–36]. Conducting an overview of reviews is a suitable method for describing the evidence across reviews and investigating the source of discrepancies. An overview of reviews uses systematic methods to identify existing systematic reviews with similar research questions for the purpose of mapping and comparing objectives, methods, and findings to develop a greater understanding of the information available. Overviews of reviews are considered suitable when multiple systematic reviews of the same topic exist but 1) the interventions are different for the same condition or population, 2) they address different approaches to the same intervention in the same population, 3) they address the same intervention but for different populations or conditions, 4) they address adverse events among different populations or 5) they address the different outcomes for the same intervention and population. In this case there are multiple systematic reviews on the topic of prolonged infusions of beta-lactam antibiotics. The populations in these reviews vary from neonates to adults and the spectrum of infections vary in site, organism and severity. The interventions studied are all prolonged infusions of a beta-lactam antibiotic, but the specific agent varies within and between sub-classes of beta-lactam antibiotics as does the method of prolonging the infusion (i.e., continuous versus extended). Finally, although mortality is the most commonly investigated outcome, other important clinical and PK/PD outcomes are variably reported. This overview of reviews addresses the following question: “In hospitalized patients with infection treated with intravenous beta-lactam antibiotics, what is the evidence from existing systematic reviews comparing prolonged with intermittent infusions of beta-lactam antibiotics for clinical outcomes including mortality, clinical and microbiological cure, length of stay, adverse events, cost and PK/PD target attainment?”

**Methods**

This overview of reviews was guided by the Cochrane Handbook [37] on methods for overviews of reviews, the PRISMA guidelines for reporting of systematic reviews [38, 39] and PRIO-harms checklist [40]. The protocol was prospectively registered in PROSPERO (CRD42019117118). Minimal deviations from the protocol were incurred; review methods
modified in accordance to the newly revised Cochrane handbook and risk of bias and quality assessment were conducted by one reviewer and verified by a second reviewer instead of being performed in duplicate (due to limited availability of resources).

**Searching the literature**

A systematic search strategy for Medline, Embase, and the Cochrane Library, was created by an experienced information specialist and reviewed by a second information specialist using the PRESS criteria (S1 Fig) [41]. PROSPERO was searched for ongoing or unreported relevant reviews and to cross reference database searches. Grey literature was searched in accordance with the Grey Matters Checklist (limited to Google, Google Scholar, the Agency for Healthcare Research Quality, Cochrane Library of Systematic Reviews using the terms beta-lactam, penicillin, carbapenem, cephalosporin, continuous, intermittent and prolonged infusions) and bibliographies of included reviews were scanned for additional reviews [42]. The search focused on reviews from January, 1990 to June, 2020, as a scoping exercise revealed no relevant systematic reviews prior to 1990.

**Study selection criteria**

Eligible systematic reviews for this overview were included based upon inclusion of the following features: (a) a systematic search of the literature with a clearly defined research question and eligibility criteria; and (b) a quantitative or narrative synthesis of extracted data. Populations were restricted to hospitalized patients with infection, without restrictions on age, infection type, or disease. Eligible reviews were required to have compared two or more infusion strategies (intermittent, extended or continuous) for administration of intravenous beta-lactam antimicrobials, with data available for clinical cure (no restrictions on definition) or mortality/survival. For reviews that reported treatment failure instead of clinical cure, the inverse was calculated and reported as treatment success or clinical cure. Secondary clinical outcomes of interest included treatment failure, microbiological cure, length of stay, adverse events, cost and emergence of resistance. Variable definitions of clinical outcomes were expected and collected but were not pre-specified during development of the methods for this overview. PK/PD outcomes of interest were probability of target attainment and $fT>MIC$.

**Processes of study selection, data extraction and analysis**

Two reviewers (AJ and PT) independently screened search results by title and abstract. Citations identified as potentially relevant by at least one reviewer underwent full text review by both reviewers independently. Discrepancies in full text screening were resolved by a third reviewer (SK). Prespecified review characteristics and outcomes of interest, as defined in their respective reviews, were extracted by two reviewers (AJ and PT), with discrepancies resolved by consensus or a third reviewer (SK). Quality assessment of each included review was conducted using the AMSTAR-2 tool (Assessing the Methodological Quality of Systematic Reviews), and risk of bias of assessments were performed using with the ROBIS tool (Risk of Bias in Systematic Reviews); all assessments were performed by one reviewer (PT) and verified by another (SK), with disagreements resolved via consensus discussion [43, 44]. Domains from AMSTAR-2 deemed to be critical to this overview included 1) protocol registration prior to starting the review, 2) adequacy of the literature search, 3) justification for study exclusions, 4) risk of bias assessment at the study level, 5) appropriateness of methods for meta-analysis, 6) consideration of risk of bias upon interpretation of results and 7) assessment of publication bias. Risk of bias at the study level and outcome level was also extracted from reviews as reported including the tools used for assessment.
Overlap of included studies was assessed using the corrected covered area (CCA) [45]. CCA calculations followed Pieper et al’s protocol according to $\text{CCA} = \frac{N}{r_c}$, where $N$ is the number of included publications (including double counting), $r$ is the number of primary publications, and $c$ is the number of reviews. Pre-determined overlap thresholds were used for interpretation of overlap (0–5%—slight, 6–10%—moderate, 11–15%—high, >15%—very high) [45]. For each outcome, a citation matrix and pairwise CCA tables were created in addition to the outcome level CCA calculations to address overlap. Overlap is presented visually as per recommendations from Pérez-Bracchiglione et al. at the 2019 Cochrane Colloquium [46].

Overview findings are reported descriptively by outcome, following Cochrane’s recommendation for overview conduct and the PRIO-harms checklist (S2 Fig) [37, 40]. Tables of study characteristics were created at the review level and at the outcome level for this evaluation. For outcomes where meta-analysis was conducted by more than two reviews, forest plots without cumulative statistics were created for visual comparison.

Results

We identified 3,407 unique records from searching electronic databases, as well as 3 additional records through hand searching of references and grey literature. 78 articles met our pre-specified criteria for full text assessment. After inspection of full texts, 21 reviews were included in this overview of systematic reviews (Fig 1) [16, 22–33, 36, 47–53]. Table 1 provides an overview of the review characteristics.

Review populations and interventions studied

The 21 reviews varied by population, intervention, and outcomes. Ten reviews did not specify the patient population studied [22, 26–28, 30, 31, 36, 48, 49, 53]. Nine reviews studied patients with acute illness, critical illness or sepsis [16, 23–25, 29, 32, 33, 47, 52]. The remaining 2 studied patients with respiratory infections [50, 51]. 9 reviews studied prolonged infusions of all beta-lactams [16, 23, 24, 26–28, 48, 50, 52]. 4 reviews studied individual classes or sub-classes of beta-lactams—cephalosporins, anti-pseudomonal beta-lactams, carbapenems and piperacillin/tazobactam [29, 36, 47, 49]. The remaining 8 reviews studied individual antimicrobials, with 7 studying piperacillin/tazobactam, 1 meropenem and 1 ceftazidime [22, 25, 28, 30–33, 53]. 3 reviews exclusively compared continuous infusions of beta-lactams with intermittent infusions [16, 23, 52], whereas the remaining 18 reviews compared all prolonged infusions with intermittent infusions. 15 reviews quantitatively analyzed outcomes of interest [16, 23–27, 29–32, 36, 47–50], whereas 6 narratively describe outcomes of interest [22, 28, 33, 51–53]. Overlap of primary studies and proportion of unique primary studies were highly variable depending on the outcome assessed, ranging from 4.8% to 13.2% and 36% to 78% respectively.

Review quality and risk of bias

Based upon findings from AMSTAR-2 evaluations that were performed to evaluate the methodological quality of included systematic reviews, almost all reviews were deemed to be of critically low or low quality. (Table 1, full assessments provided in S1 Table). Only two reviews were deemed to be of moderate quality [27, 51]. Ten reviews were deemed to have high risk of bias (Fig 2) [23, 24, 26, 28, 33, 36, 47–49, 52]. Acknowledging the overlap (and inverse relationship) between AMSTAR-2 and ROBIS discordant judgements between the two tools were primarily related to items unique to each tool.

Sixteen of 21 reviews provide study-level assessments of risk of bias using a variety of tools. Authors of one review [29] indicated they used GRADE to assess risk of bias for a subset of studies. One review stated that they used the Cochrane risk of bias tool but did not provide
information describing their evaluation [31]. None of the reviews provided a final assessment of risk of bias by outcome. Remaining reviews that included randomized controlled trials evaluated risk of bias using the Jadad scale [24, 32, 48, 50] or their own criteria [23, 28, 33, 47]. In relation to non-randomized studies, the majority of reviews used the Newcastle-Ottawa scale [24, 30, 31, 50], while three reviews used their own criteria [23, 28, 47]. Seven reviews did not report that they evaluated risk of bias at the study level at all [22, 26, 28, 36, 49, 52, 53]. Given the variable reporting and poor adherence to practice standards (i.e., GRADE framework), it was impossible to synthesize risk of bias or quality concerns of the evidence across reviews despite extracting ROB assessments at the study level as reported by authors of these reviews. For readers, we provide an example of this data in S2 Table for the first 10 randomized controlled trials in alphabetical order to highlight the variability in tools used and reporting.
| Review (author, year) | Data of last search (mm/yyyy) | Population (Disease and inclusion criteria) | Tested infusion | Comparator infusion | Antimicrobial(s) studied | Included studies | Outcomes of interest | Critical appraisal and risk of bias |
|-----------------------|-------------------------------|---------------------------------------------|----------------|-----------------|------------------------|----------------|---------------------|----------------------------------|
| Rhodes, 2018 Meta-analysis [23] | 04/2017 | Severely ill Acutely or critically ill hospitalized patients | PI II | Piperacillin/ tazobactam | RCTs | √ | √ | - | - | - | - | - | - | - | Critically low quality a |
| Vardakas, 2018 Meta-analysis [29] | 11/2016 | Adult patients with sepsis | PI II | Anti-pseudomonal beta-lactam | RCTs | √ | √ | - | - | - | √ | - | - | - | Low quality a |
| Yu, 2018 Meta-analysis [12] | 10/2018 | Severe infections | PI II | Meropenem | RCTs | √ | √ | - | - | √ | √ | - | - | - | Low quality a |
| Lee, 2017 Meta-analysis [64] | 01/2017 | Critically ill patients with predominantly respiratory infections | CI II | Beta-lactams | RCTs | √ | √ | - | - | - | - | - | - | - | Criticality low quality a |
| Ili, 2016 Meta-analysis [60] | 09/2015 | Nosocomial pneumonia | PI II | Beta-lactams | RCTs | √ | √ | - | - | √ | - | - | - | - | Low quality a |
| Roberts, 2016 Meta-analysis [66] | 12/2015 | Patients with severe sepsis or septic shock | CI II | Beta-lactams | RCTs | √ | √ | - | - | - | - | - | - | - | Low quality review a |
| Yang, 2016 Meta-analysis [16] | 09/2015 | Unspecified population | PI II | Piperacillin/ Tazobactam | RCTs | √ | √ | - | - | √ | - | - | - | - | Low quality a |
| Burgess, 2015 Qualitative review [22] | 10/2014 | Unspecified population | PI II | Cefepime | No restrictions on study design | √ | √ | - | - | √ | √ | - | - | - | Critically low quality a |
| Yang, 2015 Meta-analysis [11] | 04/2014 | Unspecified population | PI II | Piperacillin/ Tazobactam | RCTs | √ | √ | - | - | √ | - | - | - | - | Low quality a |
| Lix, 2014 Meta-analysis [51] | 06/2014 | Hospital-acquired pneumonia | PI II | Beta-lactams | No restrictions | √ | √ | - | - | - | - | - | - | - | Moderate quality a |

(Continued)
| Review (author, year) | Date of last search (mm/yyyy) | Population (Disease and inclusion criteria) | Tested infusion | Comparator infusion | Antimicrobial(s) studied | Included studies | Outcomes of interest | Critical appraisal and risk of bias |
|----------------------|-------------------------------|---------------------------------------------|----------------|-------------------|--------------------------|----------------|-------------------|----------------------------------|
| Teo, 2014            | 10/2012                        | Acute infections in hospitalized adult patients | PI II          | Beta-lactams      | RCTs                     |                | Mortality          | Low quality *                     |
| Yusuf, 2014          | 05/2014                        | Critically ill patients                      | PI II          | Piperacillin/ Tazobactam | No restrictions          |                | Mortality          | Critically low quality a         |
| Chant, 2013          | 09/2013                        | Critically ill patients                      | PI II          | Time dependent antimicrobials | Randomized and non-randomized trials | ✓  ✓ -        | Mortality, Treatment failure, Microbiologic cure | Critically low quality a         |
| Falagas, 2013        | 01/2012                        | Unspecified population                       | PI II          | Carbaopenems, piperacillin/ tazobactam | Excluded case reports and case series with <10 patients | ✓  ✓ -        | Mortality, Treatment failure, Microbiologic cure | Critically low quality a         |
| Hussain, 2013        | Not reported                   | Unspecified population                       | PI II          | Beta-lactams      | RCTs                     |                | Mortality          | Critically low quality a         |
| Korbila, 2013        | 11/2012                        | Unspecified population                       | PI II          | Cephalosporins (3rd, 4th and 5th generation) | Randomized and non-randomized trials | ✓  ✓ -        | Mortality, Treatment failure, Microbiologic cure | Critically low quality a         |
| Garcia, 2012         | Not Reported                   | Patients with acute infections susceptible to piperacillin/ tazobactam | PI II          | Piperacillin/ Tazobactam | Randomized and non-randomized trials | ✓  ✓ -        | Mortality, Treatment failure, Microbiologic cure | Critically low quality a         |
| Mih, 2012             | 09/2011                        | Adults requiring piperacillin/ tazobactam | PI II          | Piperacillin/ Tazobactam | Prospective randomized trials | ✓  ✓ -        | Mortality, Treatment failure, Microbiologic cure | Critically low quality a         |
| Tamma, 2011           | 02/2011                        | Unspecified population                       | PI II          | Beta-lactams      | RCTs                     |                | Mortality          | Moderate quality review *         |
| Roberts, 2009         | 11/2007                        | Hospitalized adults with acute infection      | PI II          | Beta-lactams      | RCTs                     |                | Mortality          | Critically low quality a         |
| Roberts, 2007         | 07/2006                        | Serious infections                           | CI II          | Beta-lactams      | No restrictions          | ✓  ✓ -        | Mortality          | Critically low quality a         |

*Quality as assessed with AMSTAR-2 tool,

b Risk of bias as assessed with ROBIS tool

PI—prolonged infusion; II—intermittent infusion; CI—continuous infusion; RCT—randomized controlled trial

https://doi.org/10.1371/journal.pone.0244966.t001
Findings, mortality

Mortality was reported in twenty reviews, with data included from 63 primary studies (S3 Table) [16, 22–33, 36, 47, 49–53]. Overlap of included primary studies across the set of twenty
reviews was high, with a CCA of 10.4% (Fig 3). Fourteen reviews performed meta-analyses of mortality [16, 23–27, 30–32, 36, 47, 49, 50, 52] while six reviews performed narrative syntheses only [22, 28, 33, 51–53].

Nine of 14 reviews [16, 24, 25, 29–32, 36, 47] show lower mortality with prolonged infusions; the five remaining reviews [23, 26, 27, 49, 50] conveyed uncertainty for effects on mortality, as the confidence intervals included the possibility of no difference and/or favoring control (Fig 4). The magnitude of effect (odds ratios) in reviews describing a mortality

---

**Fig 3.** Citation matrix for reviews reporting mortality of prolonged infusions versus intermittent infusions of beta-lactams. Green—primary studies included in systematic review, Red—primary study not included in systematic review, Black—primary studies published after systematic review and therefore ineligible for possible inclusion.

https://doi.org/10.1371/journal.pone.0244966.g003

---

**Fig 4.** Effect of prolonged versus intermittent infusions of beta-lactam antimicrobials on mortality. *Lee 2017 –Did not report event rates. RR was therefore not converted to OR. **Roberts 2016 –individual patient data analysis.

https://doi.org/10.1371/journal.pone.0244966.g004
benefit ranged from 0.53 (95% CI: 0.35–0.80) to 0.81 (95% CI: 0.67–0.99). Seven of the 9 reviews combined randomized and non-randomized mortality data for this analysis [24, 25, 30–32, 36, 47]. The 9 reviews identifying a mortality benefit were highly variable with respect to scope, quality and risk of bias. Populations of interest included adults who were hospitalized, critically ill, and being treated for severe sepsis, septic shock, and pneumonias where specified. Reviews suggesting a mortality reduction evaluated prolonged infusions of any beta-lactam, classes of beta-lactams such as carbapenems or anti-pseudomonal beta-lactams or specific beta-lactam antibiotics such as piperacillin/tazobactam and meropenem. Only two reviews specifically evaluated cephalosporins and neither identify a mortality benefit [22, 49]. Quality of conduct (per AMSTAR-2) was low or critically low for all 9 reviews identifying a mortality benefit while risk of bias at the review level (per ROBIS) was high for 2 reviews [24, 36] (Fig 2). Eight of the 9 reviews identifying a mortality benefit provide an assessment of risk of bias at the study level with variable findings [16, 24, 25, 29–32, 47]. Pairwise overlap assessment identified the reviews by Yu et al. and Roberts et al. as having slight overlap (<5%) with other reviews [16, 32] (Fig 5). This is likely explained in part by the narrow focus of these reviews where Yu et al. focused only on meropenem while Roberts et al. focused only on patients with severe sepsis and septic shock from three trials in an individual patient data meta-analysis [16, 32].

Of the five reviews failing to describe a mortality benefit, only one combined randomized and non-randomized mortality data (S3 Table) [50]. Amongst these 5 reviews, the populations were similarly diverse including critically ill adults, hospitalized patients with nosocomial pneumonia receiving prolonged or only continuous infusions of beta-lactams or cephalosporin [23, 24, 26, 49, 50]. Only reviews by Lee et al. and Lal et al. were published after 2015 [23, 50]. Only the review by Lee et al. focused on continuous infusions while all others included all prolonged infusions [23]. Quality of conduct (per AMSTAR 2) was low or critically low for all reviews except for the review by Tamma et al. which was scored as moderate [27]. Risk of bias (per ROBIS) was high for 3 of the 5 reviews failing to show a mortality benefit with prolonged infusions of beta lactams (S3 Table) [23, 26, 49]. Only 3 reviews provide risk of bias assessments at the study level (S3 Table) [23, 27, 50]. Pairwise overlap assessment between the 5 reviews that did not identify a mortality benefit show at least medium overlap (≥5%) between all reviews (Fig 4). Pairwise overlap assessment between the 9 reviews that identify a mortality benefit and the 5 reviews that did not identified several combinations with slight (<5%) overlap. The review by Korbila et al. (did not identify a mortality benefit) had slight or no overlap with 6/9 reviews that did identify a mortality benefit [49]. This review focused on 3rd, 4th and 5th generation cephalosporins, only included 6 trials in their mortality evaluation and did not include trials published after November of 2012. Reviews by Yu et al. and Roberts et al., both of whom identified a mortality benefit also had slight or no overlap with three or more negative reviews likely due to issues of scope (Yu et al. included trials of meropenem only while Roberts et al. included trials of patients with severe sepsis or septic shock) [16, 32].

Four reviews assessed the effect of study design on mortality [24, 30, 47, 50]. Three reviews found a significant mortality benefit of prolonged infusions compared to intermittent infusions in when all study designs were combined [24, 30, 47]. However, when randomized and non-randomized trials were pooled separately the mortality benefit was only identified in non-randomized trials. The remaining review failed to identify a mortality benefit when study designs were combined, nor when separated into randomized and non-randomized studies [50]. All authors conclude that mortality data from non-randomized trials may be introducing bias and that only randomized controlled trials should inform this question. It is worth re-mentioning that of the 9 reviews that identified a mortality benefit in this overview seven combined randomized and non-randomized data when pooling.
Findings, clinical cure and treatment failure

Clinical cure and treatment failure was reported in all twenty-one reviews, with data from forty-seven primary studies (S4 Table, Figs 6 and 7) [16, 22–33, 36, 47–53]. Overlap of included primary studies was high (CCA of 13.2%). Fifteen reviews performed quantitative analyses of clinical cure [16, 23–27, 29–32, 36, 48–50] including one review [47] that reported the inverse as treatment failure, while 6 reviews [22, 28, 33, 51–53] report only qualitative syntheses. Nine of 15 reviews combined data from randomized and non-randomized trials [24, 25, 30–32, 36, 47, 49, 50].

Nine of 15 reviews [16, 23–25, 31, 32, 36, 47, 50] show higher clinical cure rates with prolonged versus intermittent infusions; the 6 remaining reviews [26, 27, 29, 30, 48, 49] convey uncertainty (Fig 7). Reviews describing an improvement in clinical cure evaluated prolonged infusions of any beta-lactam and specific agents including piperacillin/tazobactam and meropenem. The two reviews specifically targeting cephalosporins did not show improved clinical

| Review             | Cure Rate | Failure Rate | CCA |
|--------------------|-----------|--------------|-----|
| Rhodes et al. 2007 | 43%       | 57%          |     |
| Rhodes et al. 2018 | 44%       | 56%          |     |
| Vardakas et al. 2018 | 44%     | 56%          |     |
| Yu et al. 2018     | 0%        | 100%         |     |
| Lee et al. 2017    | 43%       | 57%          |     |
| Lal et al. 2016    | 14%       | 86%          |     |
| Roberts et al. 2016 | 0%      | 100%         |     |
| Yang et al. 2016   | 43%       | 57%          |     |
| Burgess et al. 2015 | 17%     | 83%          |     |
| Yang et al. 2015   | 43%       | 57%          |     |
| Lux et al. 2014    | 0%        | 100%         |     |
| Teo et al. 2014    | 60%       | 40%          |     |
| Yusuf et al. 2014  | 50%       | 50%          |     |
| Falagas et al. 2013 | 22%    | 78%          |     |
| Chant et al. 2013  | 25%       | 75%          |     |
| Korbila et al. 2013 | 33%     | 67%          |     |
| Mah et al. 2012    | 17%       | 83%          |     |
| Garcia et al. 2012 | 17%       | 83%          |     |
| Tamma et al. 2011  | 63%       | 37%          |     |
| Roberts et al. 2009 | 45%     | 55%          |     |

Fig 5. Pairwise CCA for reviews reporting mortality of prolonged vs. intermittent infusions of beta-lactams. Colors indicate degree of overlap, as calculated with CCA, for visual clarity. White = ≤5%, green 5.1–9.9%, yellow 10–14.9%, red ≥15%.

https://doi.org/10.1371/journal.pone.0244966.g005
cure rates with prolonged infusions compared to intermittent infusions, one of which did not perform quantitative synthesis [22, 49]. Among the 9 reviews showing benefit, odds ratio ranged from 1.02 (95% CI: 0.47–2.26) to 2.45 (95% CI: 1.12–20.86) in 8, and relative risk was 1.18 (95% CI: 1.0065–1.3) in 1 review (Fig 7). Six of 9 reviews that identified a benefit with respect to clinical cure were in critically ill populations [23, 25, 47] or patients with severe infections [16, 32, 50], while none of the 6 remaining reviews identify their populations of interest as critically ill or having severe infections. Six reviews conducted a subgroup analysis on mortality risk [16, 23–25, 49]. The five reviews that showed higher rates of clinical cure with prolonged infusions in patients at higher risk of mortality, also showed benefit in their unstratified analyses [16, 23–25, 49]. Three of these reviews also found that patients at lower risk of mortality did have improvements of clinical cure with prolonged infusions [16, 23, 25].

Quality of conduct (per AMSTAR-2) was low or critically low for all 9 reviews identifying a clinical cure benefit, while risk of bias at the review level (per ROBIS) was high for 3 reviews [23, 24, 36] (Fig 2). Sixteen of 21 reviews provide study-level assessments of risk of bias using a variety of tools. Pairwise overlap assessment identified that the individual patient data meta-analysis of 3 trials by Roberts et al. [16] had slight (<5%) overlap with other reviews and that the reviews by Yu et al. [32] and Yang et al. [31] had no overlap as the former focused on meropenem while the latter focused on piperacillin/tazobactam (Fig 8).

Of the 6 reviews failing to identify a clinical cure benefit two combined randomized and non-randomized data [31, 49] (S4 Table). Four of these 6 reviews were published in 2013 or earlier [26, 27, 48, 49]. Quality of reporting (per AMSTAR 2) was low or critically low for all
reviews except for the review by Tamma et al. which was scored as moderate [27]. Risk of bias (per ROBIS) was high for 3 of the 6 reviews failing to show a clinical cure benefit with prolonged infusions of beta-lactams [26, 48, 49]. Only 2 reviews did not provide risk of bias assessments at the study level [26, 49]. Pairwise overlap assessment between the 6 reviews that did not identify a clinical cure benefit identified that the reviews of Yang et al. [30] and Korbila et al. [49] had no overlap as the former focused on piperacillin-tazobactam while the latter focused on cephalosporins (Fig 8). Pairwise overlap assessment between the 9 reviews identifying a clinical cure benefit and the 6 that did not, identified several combinations of slight (<5%) to no overlap that can all be explained by differences in scope (i.e., narrow drug focus [32, 49], individual patient data meta-analysis [16]).

Four reviews evaluated the effect of study design on clinical cure [24, 47, 49, 50]. Whereas 3 of 4 reviews showed clinical cure improvements, sub-group analyses of RCTs showed benefit of prolonged infusion in only one review. This review also found no benefit when exclusively assessing cohort studies [47]. Opposing this, subgroup analyses by Teo et al. showed significant benefits in the non-RCT subgroup and no benefit in the RCT subgroup, despite showing improved clinical cure globally [24]. Importantly six reviews did not perform subgroup analyses base on study design as these exclusively included RCTs [16, 23, 26, 27, 29, 48]. Four of these reviews exclusively assessing RCTs did not find significant improvements in clinical cure with prolonged infusions of beta-lactams [26, 27, 29, 48].

Findings, microbiologic cure

Microbiologic cure was reported in four reviews, with data included from eleven primary studies (S5 Table, Fig 9) [25, 31, 32, 50]. Overlap of included primary studies was moderate, with a CCA of 9.1%. Quantitative analysis of pooled microbiologic cure was performed in all four...
A definition for microbiologic cure was provided in only one review as “eradication or presumed eradication” as compared to “persistence or presumed persistence” without further explanation [31]. All four reviews combined randomized and non-randomized evidence. Only the review by Yu et al. demonstrated a statistically significant benefit regarding microbiologic cure with prolonged infusions [32] (Fig 10). Notably, this review focused on meropenem prescribed for acute infections while the reviews by Rhodes et al. and Yang et al. [25, 31] focused only on piperacillin/tazobactam and the review by Lal et al. [50] included all beta-lactam antimicrobials but limited infections to nosocomial pneumonia. Despite the overall moderate overlap, pairwise overlap assessment confirms that the review by Yu et al. [32] included four primary studies [55–58] not found in the other three reviews and has no overlap with either of the 3 reviews that did not find a microbiological cure benefit with prolonged infusions when compared with intermittent administration (Fig 11). Predictably only the reviews by Yang et al. and Rhodes et al. had overlap (60%) given that they both focused on piperacillin/tazobactam [25, 31].

Fig 8. Pairwise CCA of reviews reporting clinical cure of prolonged versus intermittent infusions of beta-lactams. Colors indicate degree of overlap, as calculated with CCA, for visual clarity. White = ≤ 5%, green 5.1–9.9%, yellow 10–14.9%, red ≥ 15%.

https://doi.org/10.1371/journal.pone.0244966.g008
Quality of conduct (per AMSTAR-2) was low or critically low for all 4 reviews evaluating microbiologic cure while risk of bias at the review level (per ROBIS) was low for all 4 reviews [25, 31, 32, 50] (Fig 2). Study level risk of bias was assessed using a variety of tools (Cochrane Risk of Bias Tool, Jadad Scale, Newcastle Ottawa Scale) in all 4 reviews overall but none at the outcome level. The review by Lal et al. stated that they used the Jadad and Newcastle Ottawa Scale but the data are not reported [50].

![Fig 9. Citation matrix for reviews reporting microbiologic cure of prolonged infusions. Green—primary studies included in systematic review, Red—primary study not included in systematic review, Black—primary studies published after systematic review and therefore ineligible for possible inclusion.](https://doi.org/10.1371/journal.pone.0244966.g009)

![Fig 10. Effect of prolonged infusions versus intermittent infusions of beta-lactam antimicrobials on microbiologic cure.](https://doi.org/10.1371/journal.pone.0244966.g010)
Findings, length of stay

Length of stay was reported in eight reviews, with data included from 37 primary studies (S6 Table, Fig 12) [22, 25, 28, 30, 32, 33, 47, 52]. Overlap of included primary studies was moderate with CCA of 7.7%. Two reviews assessed length of stay quantitatively [25, 47] while six reviews provide only qualitative assessments [34, 46, 47, 53, 57, 62].

Neither of the two quantitative analyses showed a significant reduction in hospital or ICU LOS [25, 47]. In the review by Rhodes et al. focusing on piperacillin/tazobactam in critically ill patients, the ratio of means from 12 studies evaluating hospital length of stay in 2,916 patients showed a numerical lower, but insignificant, reduction with prolonged infusions 0.92 (95% CI: 0.83–1.03; I² = 39%) [25]. The ratio of means from 10 studies evaluating ICU length of stay in 2593 patients was reported as 1.04 (95% CI: 0.87–1.25; I² = 66.2%). Subgroup analysis by risk of mortality (20% threshold) also showed no benefit of prolonged infusions when compared
with intermittent infusions. The review by Chant et al. evaluating prolonged infusions of all
time dependent antibiotics (one trial each of prolonged infusions of linezolid and vancomycin
were included) in critically ill patients report a mean difference from 9 studies enrolling 1417
patients of -1.08 days (95% CI: -4.25 to 2.10; I^2 = 56%) [47]. While statistically non-significant,
the trend towards benefit with prolonged infusions appears to be driven by non-randomized
trials. The mean difference from 4 randomized trials (n = 315) was 4.90 days (95% CI: -1.83 to
11.64; I^2 = 8%), while the mean difference from 5 non-randomized trials (n = 1102) was -2.38
days (95% CI: -5.04 to 0.28; I^2 = 29%). The mean difference in ICU length of stay between pro-
longed infusions from 11 trials enrolling 1495 patients in the review by Chant et al. was -1.02
days (95% CI: -2.65 to 0.60; I^2 = 60%) [47]. In this case the sensitivity analysis by study design
did identify a statistically significant benefit with prolonged infusions on ICU length of stay
whereby the mean difference among 5 randomized trials (n = 444) was -1.5 days (95% CI: -2.81 to
-0.19; I^2 = 0). The mean difference in ICU length of stay from 6 non-randomized trials
(n = 1053) was not statistically significant at -0.86 days (95% CI: -3.60 to 1.88; I^2 = 73%). Pair-
wise overlap assessment between these two reviews reveal moderate overlap with the review by
Rhodes et al. focusing on only piperacillin/tazobactam while the review by Chant (2013) et al
included a much broader range of time dependent antibiotics [25, 47] (Fig 13). Furthermore,
given the 5 year difference in publication dates 12 trials included by other reviews were pub-
lished after Chant et al in 2013.

Quality of conduct (per AMSTAR-2) was critically low for both reviews with quantitative
evaluations of length of stay [25, 47]. Risk of bias at the review level (per ROBIS) was low for
both reviews (Fig 2) [25, 47]. Study level risk of bias was assessed in both reviews but the tool
used by Chant et al. is not clear [47]. ROB was assessed by neither review at the outcome level.

Findings, adverse events

Adverse events were reported in 14 reviews, with data included from 34 primary studies (S7
Table, Fig 14) [22, 24, 27–29, 31–33, 49–53, 59]. Overlap of included studies was slight, with a
CCA of 4.8% (acknowledging that the review by Vardakas et al. did not identify the trials they included in the evaluation of this outcome) [29].

The review by Vardakas et al. found no difference after meta-analysis of adverse events rates from seven unspecified RCTs enrolling 980 patients (RR 0.88; 95%CI: 0.71–1.09):

| Study               | 2007            | 2018            | 2015            | 2016            | 2014            | 2013            |
|---------------------|-----------------|-----------------|-----------------|-----------------|-----------------|-----------------|
| Rhodes et al. 2018  | 17%             |                 |                 |                 |                 |                 |
| Yu et al. 2018      | 0%              | 0%              |                 |                 |                 |                 |
| Yang et al. 2016    | 14%             | 22%             | 0%              |                 |                 |                 |
| Burgess et al. 2015 | 20%             | 0%              | 0%              | 0%              |                 |                 |
| Yusuf et al. 2014   | 50%             | 20%             | 0%              | 33%             | 0%              |                 |
| Chant et al. 2013   | 50%             | 6%              | 8%              | 5%              | 7%              | 13%             |
| Mah et al. 2012     | 20%             | 40%             | 0%              | 38%             | 0%              | 13%             |

Fig 13. Pairwise CCA for reviews reporting length of stay of prolonged versus intermittent infusions of beta-lactams. Colors indicate degree of overlap, as calculated with CCA, for visual clarity. White = ≤5%, green 5.1–9.9%, yellow 10–14.9%, red ≥15%.

https://doi.org/10.1371/journal.pone.0244966.g013
I^2 = 0%) [29]. Thirteen reviews qualitatively described findings from primary studies. All reviews described studies that did not find a difference in rate of adverse events [22, 24, 27, 28, 31–33, 49–53, 59]. Of these, three reviews [21, 28, 52] described the findings of one study [60] that attributed serious adverse to 6 patients with complicated intra-abdominal infections randomized to receive a continuous infusion of piperacillin/tazobactam including *Clostridium difficile* colitis, renal failure, confusion, tachycardia, and a tonic/clonic seizure. This study did not find significant differences in the rate of serious adverse events between continuous and intermittent infusion groups and none of the adverse events were associated with death. One review [32] described a significant increase in acute kidney injury with intermittent versus prolonged infusion of meropenem in neonates in one trial [56]. Tamma et al. noted that almost all studies did not define adverse events *a priori* [27]. The extreme variability in rate of adverse events was also noted in one review, where rate of adverse events of included studies ranged from 0% to 89% [52]. Pairwise overlap assessment between the review by Vardakas et al. and the other 13 reviews with narrative assessments of adverse events was inconclusive as Vardakas et al. did not identify the individual trials informing this outcome (Fig 15) [29].

Quality of conduct (per AMSTAR-2) for the Vardakas et al. review was low as was their risk of bias (per ROBIS) [29]. The quality of reporting and risk of bias for the remaining reviews varied widely. Study level risk of bias was not performed in 3 of 14 reviews [22, 36, 49] and no review conducted a risk of bias assessment at the outcome level.
Table 1. Pairwise CCA for reviews reporting adverse events or prolonged versus intermittent infusions of beta-lactams. Colors indicate degree of overlap, as calculated with CCA, for visual clarity. White = ≤5%, green 5.1–9.9%, yellow 10–14.9%, red ≥15%. N/A indicated where primary studies included were not reported by systematic review.

https://doi.org/10.1371/journal.pone.0244966.g015

**Findings, cost**

Costs of prolonged versus intermittent infusions of beta-lactams were reported in five reviews, with data included from 9 primary studies (S8 Table, Fig 16) [28, 30, 31, 52, 53]. Overlap of included primary studies was moderate, with a CCA of 8.3%. One review by Yang et al. that focused on piperacillin/tazobactam in an unspecified population performed a meta-analysis of healthcare cost data from three studies (n = 2298) and described mean difference of -0.38 (95% CI: -0.70 to -0.07; I² = 61%) in favor of prolonged infusions when compared with traditional dosing [27]. Further sensitivity analysis by study design reveal that this cost benefit in favor of prolonged infusions was evident in one randomized trial (n = 50; mean difference -0.94; 95% CI: -1.52 to -0.35) as well as in two non-randomized studies (n = 2248; mean difference -0.25; 95% CI: -0.34 to -0.16; I² = 0%).
In other reviews with descriptive reporting Roberts et al. report on one primary study that showed significant cost reduction in aggregate costs related to drug procurement, preparation, administration, adverse events and therapeutic failure [52]. Similarly, Garcia et al. report on one other primary study that showed reduction in aggregate costs related to drug preparation, administration, adverse events and therapeutic failure, but not drug procurement costs [53] related to prolonged infusions. Two reviews only discuss cost implications of prolonged infusions in their discussion sections. Both reviews highlighted positive findings with regards to cost, however no conclusions are provided by the authors and the presented findings do not appear to be the product of a systematic review of cost related outcomes of included studies [28, 31]. Pairwise overlap assessment suggests that the review by Yang (2016) has very high overlap with their prior review (Yang (2015) et al) and Mah et al. (Fig 17) [28, 30, 31].

Quality of conduct (per AMSTAR-2) for the Yang et al. review was low as was their risk of bias (per ROBIS) [30]. The quality of reporting and risk of bias for the remaining reviews varied widely. Study level risk of bias was performed by all reviews but not at the outcome level.

**Findings, emergence of antimicrobial resistance**

Emergence of resistance with prolonged infusions of beta-lactams was evaluated in four reviews, with data included from nine primary studies (S9 Table, Fig 18) [29, 36, 49, 51]. Overlap of

---

[Image and Table]: Fig 16. Citation matrix for reviews reporting cost of prolonged versus intermittent infusions of beta-lactams. Green—primary studies included in systematic review, Red—primary study not included in systematic review, Black—primary studies published after systematic review and therefore ineligible for possible inclusion.

https://doi.org/10.1371/journal.pone.0244966.g016
included studies moderate with a CCA of 7.4% (of note, the review by Vardakas [29] et al. did not identify the individual trials informing this outcome and this is reflected in the CCA calculation). The relationship between antimicrobial resistance was evaluated descriptively in all reviews except for the review by Vardakas et al. which focused on anti-pseudomonal beta-lactam antibiotics in septic patients [29]. In their review, two unidentified randomized trials showed no difference in the development of resistance between prolonged and intermittent infusions (RR 0.60, 95% CI: 0.15 to 2.38) [29]. They also report that two other unidentified randomized trials identified no resistant strains in either treatment group [29]. In the review by Falagas et al. evaluating carbapenems and piperacillin/tazobactam in an unspecified population

| Review           | Year | Percentage |
|------------------|------|------------|
| Yang et al. 2016 | 0%   | 0%         |
| Yang et al. 2015 | 0%   | 20%        |
| Garcia et al. 2012 | 0% | 0%         | 0% |
| Mah et al. 2012  | 0%   | 25%        | 40% | 0% |

Fig 17. Pairwise CCA for reviews reporting cost of prolonged versus intermittent infusions of beta-lactams. Colors indicate degree of overlap, as calculated with CCA, for visual clarity. White = ≤5%, green 5.1–9.9%, yellow 10–14.9%, red ≥15%. N/A indicated where primary studies included were not reported by systematic review.

https://doi.org/10.1371/journal.pone.0244966.g017
five studies were identified, four of which did not identify antimicrobial resistance in any treatment group [36]. They identified that one trial [61] reported two clinical isolates that developed resistance during therapy with continuous infusions of piperacillin/tazobactam but the quality of reporting was insufficient for evaluation. Lux et al. intended to evaluate antibiotic resistance in their review involving all beta lactams used for hospital acquired pneumonia but deemed that one RCT and one retrospective cohort that they identified to have insufficient evidence for analysis [51]. Finally the review by Korbila et al. that evaluated cephalosporine infusions in an unspecified population identified 3 trials that evaluated antimicrobial resistance, from which only one trial [62] found that 12% of patients in the intermittent infusion arm developed resistant isolates compared with none in the extended or continuous infusion group [49]. Given the variability in scope between these review pairwise assessment of overlap identified that only the review by Lux et al., which evaluated all beta lactams, had identifiable overlap with reviews by Korbila et al. and Falagas et al. (Fig 19) [36, 49, 51].

Quality of conduct (per AMSTAR-2) for the Vardakas et al. review was low as was their risk of bias (per ROBIS) [29]. The quality of reporting and risk of bias for the remaining reviews varied widely. Study level risk of bias was performed by all reviews but not at the outcome level.

**Findings, pharmacokinetic/pharmacodynamic outcomes**

PK/PD outcomes were reported in six reviews, with data from 29 primary studies (S10 Table, Fig 20) [22, 23, 28, 51–53]. Overlap of included studies was slight, with mCCA of 4.8%. Of
these 6 reviews only 3 report the outcomes of interest: $fT > \text{MIC}$ and the probability of PD target attainment [22, 23, 28]. None performed meta-analysis of this outcome.

The review by Lee et al. evaluating beta-lactam antibiotics in critically ill patients with respiratory infections identified 11 trials evaluating $fT > \text{MIC}$ [23]. In these 11 trials the $fT > \text{MIC}$ for the prolonged infusion treatment arms was 97–100% while in the intermittent bolus arms the $fT > \text{MIC}$ ranged from 46–100% using MICs of susceptible strains. The authors report that statistically significant differences were only found in 3 of 11 trials all in favor of continuous

![Table](https://doi.org/10.1371/journal.pone.0244966.g019)
infusions [23]. The review by Burgess et al. only included trials of cefepime and identified 3 trials in critically ill patients reporting \( fT > MIC \) and the probability of target (\( > 50\% fT > MIC \)) attainment using Monte Carlo simulation [22]. In these trials the \( fT > MIC \) ranged from 50 to 65% and the simulation studies suggest that 4g per day administered as a continuous or prolonged infusion would be required for \( > 90\% \) target attainment [22]. The review by Mah et al. focusing on piperacillin/tazobactam identified 4 trials that compare the probability of target attainment (\( > 50\% fT > MIC \)) [28]. Amongst these trials, prolonged or continuous infusion of at least 13.5g per day were required to achieve \( > 90\% \) probability of target attainment in a variety of hospitalized patients. No dosing strategy involving traditional infusions of piperacillin/tazobactam achieved this target of \( > 90\% \) probability [28]. Pairwise overlap assessment between these 3 reviews reveal high overlap between reviews by Burgess et al. and Mah et al. and moderate overlap between reviews by Lee et al. and Mah et al. (Fig 21) [22, 23, 28]. The latter is expected due to similarities in scope despite the 5 years between publications. The overlap between Burgess et al. and Mah et al. is unexpected given the focus on different antimicrobials [22, 28]. This evaluation of overlap may be overestimated due to the fact that some of the primary studies included in both reviews provide PK data on multiple antimicrobials.

Quality of reporting (per AMSTAR-2) for all three reviews discussed were critically low. Risk of bias (per ROBIS) was high for reviews by Lee et al. and Mah et al. and low for the review by Burgess et al. [22, 23, 28]. Study level risk of bias was performed in all reviews except Burgess et al. and no review performed an assessment of risk of bias at the outcome level.

**Discussion**

Our overview of systematic reviews identified 21 reviews evaluating effects of prolonged infusions of beta-lactams on clinical cure or mortality. Considerable variability was seen across populations, beta-lactams, infusion protocol and outcomes and their definitions. These differences preclude us from broadly generalizing the benefits of prolonged infusions of beta-lactam antimicrobials. Rather, the current body of systematic reviews and primary studies present a
|                          | Roberts et al. 2007 | Lee et al. 2017 | Burgess et al. 2015 | Lux et al. 2014 | Garcia et al. 2012 |
|--------------------------|---------------------|----------------|---------------------|----------------|-------------------|
| Lee et al. 2017          |                     | 8%             |                     |                |                   |
| Burgess et al. 2015      |                     | 20%            | 0%                  |                |                   |
| Lux et al. 2014          | 0%                  |                | 11%                 | 0%             |                   |
| Garcia et al. 2012       | 0%                  | 0%             | 0%                  | 0%             | 0%                |
| Mah et al. 2012          | 0%                  | 8%             | 15%                 | 17%            | 0%                |

Fig 21. Pairwise CCA for reviews reporting PK/PD outcomes of prolonged versus intermittent infusion of beta-lactams. Colors indicate degree of overlap, as calculated with CCA, for visual clarity. White = ≤5%, green 5.1–9.9%, yellow 10–14.9%, red ≥15%. N/A indicated where primary studies included were not reported by systematic review.

https://doi.org/10.1371/journal.pone.0244966.g021
fragmented picture of the use and impact of prolonged infusions of beta-lactam antimicrobials in different clinical contexts. It does appear that with respect to the outcomes of mortality and clinical cure, the populations where benefits were observed most often were critically ill patients or those with serious infections. Furthermore, the sub-classes of beta-lactams most often studied were penicillins (particularly piperacillin-tazobactam) and carbapenems (particularly meropenem). Most reviews combined extended and continuous infusions under the umbrella of prolonged infusions, and thus there was insufficient evidence to comment on differences between infusion strategies. Although the reviews that reported on PD target attainment identified that prolonged infusions were significantly more likely to result in PD target attainment when compared to traditional dosing, no review compared the probability of PD target attainment between extended and continuous infusions. The outcomes of interest with the most evidence were mortality and clinical cure. Mortality was improved with prolonged infusions of beta-lactams in most reviews in a variety of hospitalized patients including critically ill and those with pneumonias. Reviews that focused on cephalosporins were few and did not identify a mortality benefit. However, among reviews that evaluated study design in sensitivity analyses, all authors suggest that meta-analyses of non-randomized studies may introduce bias due to residual confounding and selection bias. It is important to recognize that 7 of 9 reviews that identified a mortality benefit combined randomized and non-randomized data, while 4 of 5 reviews that did not identify a mortality benefit only evaluated randomized controlled trials. Similarly, most (9 of 15) reviews evaluating clinical cure (albeit variably defined) describe a benefit in patients receiving prolonged infusions as compared with intermittent infusions, however bias introduced by including non-randomized studies may have influenced this outcome. With both of these outcomes, the reviews that conducted subgroup analyses by severity of illness suggest that benefit may be greater in more severely ill patients as compared with less sick patients. The other outcomes of interest including microbiologic cure, length of stay, adverse events, cost, emergence of antimicrobial resistance and PK/PD outcomes were less well informed. Microbiologic cure was only improved by prolonged infusions of meropenem in one of four reviews. Two reviews evaluating length of stay quantitatively did not find a difference between prolonged and intermittent infusions. Adverse events were poorly reported in primary studies and thus reviews were also inconsistent in their evaluation of adverse events. The one review that performed a meta-analysis of cost data did associate a healthcare cost savings with prolonged infusions from 3 trials. While 4 reviews addressed antimicrobial resistance, the effect of prolonged infusions of beta-lactams on this outcome remains uncertain. Finally, despite only 3 reviews addressing PK/PD outcomes, prolonged infusions appear to maximize $f_T>\text{MIC}$, and this may lead to a greater chance of PD target attainment. The evidence describing the relationship between target attainment and clinical outcomes was insufficient. While mortality and clinical cure outcomes were well represented in these reviews, we strongly feel that all these outcomes are important and future reviews and trials should address them with equal attention.

It must be recognized that the quality of reviews and risk of bias assessment at the study level and the review level was variable but generally poor. Poor quality conduct of reviews impedes decision making and represents waste in use of research dollars [63, 64]. Assessing the risk of bias of included evidence is an important step of conduct for systematic reviews, for which the evidence needs to be properly contextualized for the reader to understand to what extent they should be placing confidence in those findings. The GRADE framework is an internationally-endorsed best practice approach for understanding the certainty of evidence findings that formally includes the risk of bias assessment of the body of evidence along with other considerations to evaluate the confidence or certainty of the evidence. Undertaking GRADE assessments is integral to systematic review work to ‘set-the-stage’ for the use of findings in healthcare decision-making. With the exception of Roberts et al. [26] and Tamma et al. [27], it
is conceivable that most reviews could have made use of GRADE methodology to interpret the evidence for readers. This means that, despite reports of effectiveness in some reviews, readers are left without a complete assessment of whether those results have sufficient certainty for applying in practice. Therefore, we suggest that future authors of systematic reviews consult GRADE’s published guidance or their online or in-person training offerings to implement use of this methodology. Given poor adherence to best practice standards and variability in interpretation of assessments across reviews, it was difficult for us to both provide a summary of the risk of bias or quality concerns of the evidence and to interpret this for readers.

We have identified numerous gaps in the current body of systemic reviews assessing clinical outcomes of prolonged infusions of beta-lactams. For one, the impact of concomitant non-beta-lactam antimicrobial therapy was not addressed consistently across reviews. Secondly, differences in total daily dose between infusion strategies was not regularly addressed. Studies originally touted prolonged infusion protocols as a potential cost saving mechanism, assuming similar efficacy of reduced dose prolonged infusion to full dose intermittent infusions of beta-lactams. However, given generally well tolerated beta-lactam antimicrobial therapies and the goal of improved clinical outcomes, it is imperative that systematic reviews assess the effect of prolonged infusions with consistent total daily doses. Finally, although beta-lactams doses and frequencies are regularly adjusted for patient specific PK/PD variations, such as impaired renal function and extremes of body weight, no review attempted to account for this or commented. We recognize that the gaps identified in systematic reviews may not reflect corresponding knowledge gaps in primary studies. However, systematic reviews should too describe gaps in included studies to guide future randomized control studies.

Our overview is primarily limited by the quality of included systematic reviews. Quality of included systematic reviews, as assessed with AMSTAR-2, was generally low given common critical deficiencies (i.e. lack of predetermined protocol and well-defined search strategies). Risk of bias, as assessed with the ROBIS tool, often highlighted the same deficiencies given overlapping criteria. Given that methodologic deficiencies were generally common to included reviews, we did not adjust or exclude reviews of lower quality or higher risk of bias. Rather, we have highlighted these to facilitate appropriate interpretation of findings. To capture all relevant reviews, we broadly searched multiple databases, with a peer reviewed search strategy developed by an experience information specialist. Despite this rigorous process, included systematic reviews may have systematically omitted primary studies introducing a selection or publication bias in the findings of our overview. Due to the wide variety of tools used to assess risk of bias and a lack of risk of bias assessment at the outcome level we were unable to synthesize this data in a meaningful way, and resource restrictions precluded us from taking the additional step of re-assessing all primary studies using appropriate tools for the study design. Discrepancies and variations in constructs in the risk of bias assessments make it difficult to truly assess risk of bias for the primary studies. Although overlap, as measured by CCA, was generally moderate to high for each clinical outcome studied, percentage of unique references ranged from 38–78%. Thus, as is typical of overviews, our findings are more strongly impacted by primary studies found in multiple reviews than not.

**Conclusion**

This overview of reviews aimed to map and compare of objectives, methods, and findings of existing systematic reviews investigating prolonged beta-lactam infusions. A systematic and comprehensive review of the literature revealed a wealth of literature, both systematic reviews and primary studies. Despite this, conclusions across reviews on the same topic were inconsistent and potentially biased. Findings from our overview clearly demonstrate a consistent and
reproducible lack of harm with prolonged infusions. However, when qualifying and quantifying benefit of prolonged infusions of beta-lactams there is variability in effect size and significance of benefits of prolonged infusions. Findings of reduced mortality and improved rates of clinical cure should be tempered by presumed risk of bias. Despite 21 systematic reviews addressing prolonged infusions of beta-lactams, this overview supports the need for better conducted reviews and continued need for definitive trials given variability in scope of the available systematic reviews. Subsequent systematic reviews should only include well designed RCTs and should specifically evaluate the proposed benefits found in various subgroup-analyses—i.e. high risk of mortality. Given the generally low quality and variable risk of bias of included reviews, future systematic review should employ rigorous methods in keeping with AMSTAR-2 and ROBIS recommendations.

Supporting information

S1 Table. AMSTAR results of included reviews. AMSTAR criterion: 1 –Did the research question and inclusion criteria for the review include the components of PICO?; 2 –Did the report of the review contain an explicit statement that the review methods were established prior to the conduct of the review and did the report justify any significant deviations from the protocol?; 3 –Did the review authors explain their selection of the study designs for inclusion in the review?; 4 –Did the review authors use a comprehensive literature search strategy?; 5 –Did the review authors perform study selection in duplicate?; 6 –Did the review authors perform data extraction in duplicate?; 7 –Did the review authors provide a list of excluded studies and justify the exclusions?; 8 –Did the review authors describe the included studies in adequate detail?; 9 –Did the review authors use a satisfactory technique for assessing ROB in individual studies that were included in the review? 9a –RCT, 9b –NRSA; 10 –Did the review authors report on the sources of funding for the studies included in the review?; 11 –If meta-analysis was performed did the review authors use appropriate methods for statistical combination of results? 11a –RCT; 11b –NRSA; 12 –If meta-analysis was performed, did the review authors assess the potential impact of ROB in individual studies on the results of the meta-analysis or other evidence synthesis?; 13 –Did the review authors account for ROB in individual studies when interpreting/discussing the results of the review?; 14 –Did the review authors provide a satisfactory explanation for, and discussion of, any heterogeneity observed in the results of the review?; 15 –If they performed quantitative synthesis did the review authors carry out an adequate investigation of publication bias (Small study bias) and discuss its likely impact on the results of the review?; 16 –Did the review authors report any potential sources of conflict of interest, including any funding they received for conducting the review? Abbreviations: Y—Yes; PY—Partial Yes; N—No; NA—Not Applicable; CL—critically low quality; L—low quality; M—moderate quality. (DOCX)

S2 Table. Risk of bias and/or quality assessments of primary studies as reported in included reviews. NOS—Newcastle Ottawa Scale; ROB—Risk of bias. (DOCX)

S3 Table. Characteristics of reviews reporting mortality. * Subsequent sensitivity analyses conducted to separate randomized and non-randomized trials, PI—prolonged infusion, II—intermittent infusion, AMSTAR-2—assessing the methodologic quality of systematic reviews, ROBIS—risk of bias tool for systematic reviews. (DOCX)

S4 Table. Characteristics of reviews reporting clinical cure or treatment failure. * Subsequent sensitivity analyses conducted to separate randomized and non-randomized trials, PI—
prolonged infusion, II—intermittent infusion, AMSTAR-2—assessing the methodologic quality of systematic reviews, ROBIS—risk of bias tool for systematic reviews.

(S5 Table. Characteristics of reviews reporting microbiologic cure. PI—prolonged infusion, II—intermittent infusion, AMSTAR-2—assessing the methodologic quality of systematic reviews, ROBIS—risk of bias tool for systematic reviews.

(S6 Table. Characteristics of reviews reporting length of stay. a Subsequent sensitivity analyses conducted to separate randomized and non-randomized trials, CI—Continuous infusion, PI—prolonged infusion, II—intermittent infusion, AMSTAR-2—assessing the methodologic quality of systematic reviews, ROBIS—risk of bias tool for systematic reviews.

(S7 Table. Characteristics of reviews reporting adverse events. CI—Continuous infusion, PI—prolonged infusion, II—intermittent infusion, AMSTAR-2—assessing the methodologic quality of systematic reviews, ROBIS—risk of bias tool for systematic reviews.

(S8 Table. Characteristics of reviews reporting cost. a Subsequent sensitivity analyses conducted to separate randomized and non-randomized trials, PI—prolonged infusion, II—intermittent infusion, AMSTAR-2—assessing the methodologic quality of systematic reviews, ROBIS—risk of bias tool for systematic reviews.

(S9 Table. Characteristics of reviews reporting emergence of resistance. PI—prolonged infusion, II—intermittent infusion, AMSTAR-2—assessing the methodologic quality of systematic reviews, ROBIS—risk of bias tool for systematic reviews.

(S10 Table. Characteristics of reviews reporting PK/PD outcomes. PI—prolonged infusion, II—intermittent infusion, AMSTAR-2—assessing the methodologic quality of systematic reviews, ROBIS—risk of bias tool for systematic reviews.

(S1 Fig. Search strategy.

(S2 Fig. PRIO-harms checklist.

Acknowledgments
We would like to acknowledge Becky Skidmore, MLIS and Lindsey Sikora, MLIS for developing, conducting, and reviewing the search strategy. We would also like to acknowledge Carole Lunny, MPH, PhD for reviewing the manuscript prior to publication.

Author Contributions
Conceptualization: Pierre Thabet, Erika MacDonald, Salmaan Kanji.

Data curation: Pierre Thabet, Anchal Joshi, Salmaan Kanji.

Formal analysis: Pierre Thabet, Salmaan Kanji.
Methodology: Pierre Thabet, Erika MacDonald, Brian Hutton, Wei Cheng, Adrienne Stevens, Salmaan Kanji.

Project administration: Pierre Thabet, Salmaan Kanji.

Resources: Pierre Thabet.

Supervision: Salmaan Kanji.

Visualization: Adrienne Stevens, Salmaan Kanji.

Writing – original draft: Pierre Thabet, Salmaan Kanji.

Writing – review & editing: Pierre Thabet, Anchal Joshi, Erika MacDonald, Brian Hutton, Wei Cheng, Adrienne Stevens.

References

1. Angus DC, Linde-Zwirble WT, Lidicker J, Clermont G, Carcillo J, Pinsky MR. Epidemiology of severe sepsis in the United States: analysis of incidence, outcome, and associated costs of care. Crit Care Med. 2001; 29(7):1303–10. https://doi.org/10.1097/00003246-200107000-00002 PMID: 11445675

2. Polat G, Ugan RA, Cadirci E, Halici Z. Sepsis and Septic Shock: Current Treatment Strategies and New Approaches. Eurasian J Med. 2017; 49(1):53–8. https://doi.org/10.5152/eurasianmed.2017.17062 PMID: 28416934

3. Gao H, Evans TW, Finney SJ. Bench-to-bedside review: sepsis, severe sepsis and septic shock—does the nature of the infecting organism matter? Crit Care. 2008; 12(3):213. https://doi.org/10.1186/cc6862 PMID: 1846647

4. Vincent JL, Abraham E. The last 100 years of sepsis. Am J Respir Crit Care Med. 2006; 173(3):256–63. https://doi.org/10.1164/rccm.200510-1604OE PMID: 16239619

5. Rhodes A, Evans LE, Alhazzani W, Levy MM, Antonelli M, Ferrer R, et al. Surviving Sepsis Campaign: International Guidelines for Management of Sepsis and Septic Shock: 2016. Crit Care Med. 2017; 45(3):486–552. https://doi.org/10.1097/CCM.0000000000002255 PMID: 28098591

6. Kumar A. Optimizing antimicrobial therapy in sepsis and septic shock. Crit Care Clin. 2009; 25(4):733–51, viii. https://doi.org/10.1016/j.ccc.2009.08.004 PMID: 19892250

7. Martinez MN, Papich MG, Drusano GL. Dosing regimen matters: the importance of early intervention and rapid attainment of the pharmacokinetic/pharmacodynamic target. Antimicrob Agents Chemother. 2012; 56(6):2795–805. https://doi.org/10.1128/AAC.05360-11 PMID: 22371890

8. Roberts JA, Paul SK, Akova M, Bassetti M, De Waele JJ, Dimopoulos G, et al. DALI: Defining Antibiotic Levels in Intensive care unit patients: Are current beta-lactam antibiotic doses sufficient for critically ill patients? Clin Infect Dis. 2014. https://doi.org/10.1093/cid/ciu027 PMID: 24429437

9. Seyler L, Cotton F, Taccone FS, De Backer D, Macours P, Vincent JL, et al. Recommended beta-lactam regimens are inadequate in septic patients treated with continuous renal replacement therapy. Crit Care. 2011; 15(3):R137. https://doi.org/10.1186/cc10257 PMID: 21649882

10. Taccone FS, Laterre PF, Dugernier T, Spapen H, Delattre I, Wittebole X, et al. Insufficient beta-lactam concentrations in the early phase of severe sepsis and septic shock. Crit Care. 2010; 14(R):R126. https://doi.org/10.1186/cc9091 PMID: 20594297

11. Nicolau DP. Pharmacodynamic optimization of beta-lactams in the patient care setting. Crit Care. 2008; 12 Suppl 4:S2. https://doi.org/10.1186/cc6818 PMID: 18495059

12. Kuti JL. OPTIMIZING ANTIMICROBIAL PHARMACODYNAMICS: A GUIDE FOR YOUR STEWARDSHIP PROGRAM. Revista Médica Clínica Las Condes. 2016; 27(5):615–24.

13. Guilhamou R, Benaboud S, Bennis Y, Dahyot-Fizelier C, Dailly E, Gandia P, et al. Optimization of the treatment with beta-lactam antibiotics in critically ill patients—guidelines from the French Society of Pharmacology and Therapeutics (Société Française de Pharmacologie et Thérapeutique—SFTP) and the French Society of Anaesthesia and Intensive Care Medicine (Société Française d’Anesthésie et Réanimation—SFAR). Critical Care. 2019; 23(1):104. https://doi.org/10.1186/s13054-019-2378-9 PMID: 30925922

14. Muller AE, Punt N, Mouton JW. Optimal exposures of ceftazidime predict the probability of microbiological and clinical outcome in the treatment of nosocomial pneumonia. The Journal of antimicrobial chemotherapy. 2013; 68(4):900–6. https://doi.org/10.1093/jac/dks468 PMID: 23190766
15. Lodise TP, Lomaestro B, Drusano GL. Piperacillin-tazobactam for Pseudomonas aeruginosa infection: clinical implications of an extended-infusion dosing strategy. Clin Infect Dis. 2007; 44(3):357–63. https://doi.org/10.1086/510590 PMID: 17205441

16. Roberts JA, Abdul-Aziz MH, Davis JS, Dulhunty JM, Cotta MO, Myburgh J, et al. Continuous versus Intermittent beta-Lactam Infusion in Severe Sepsis. A Meta-analysis of Individual Patient Data from Randomized Trials. Am J Respir Crit Care Med. 2016; 194(6):681–91. https://doi.org/10.1164/ajccm.201601-0024OC PMID: 26974879

17. De Waele JJ, Lipman J, Akova M, Bassetti M, Dimopoulos G, Kaukomen M, et al. Risk factors for target non-attainment during empirical treatment with β-lactam antibiotics in critically ill patients. Intensive care medicine. 2014; 40(9):1340–51. https://doi.org/10.1007/s00134-014-3403-8 PMID: 25053248

18. Bauer KA, West JE, O’Brien JM, Goff DA. Extended-infusion cefepime reduces mortality in patients with Pseudomonas aeruginosa infections. Antimicrob Agents Chemother. 2013; 57(7):2907–12. https://doi.org/10.1128/AAC.02365-12 PMID: 23571547

19. Feher C, Rovira M, Soriano A, Esteve J, Martinez JA, Marco F, et al. Effect of meropenem administration in extended infusion on the clinical outcome of febrile neutropenia: a retrospective observational study. J Antimicrob Chemother. 2014; 69(9):2556–62. https://doi.org/10.1093/jac/dku150 PMID: 24855125

20. Felton TW, Goodwin J, O’Connor L, Sharp A, Gregson L, Livermore J, et al. Impact of Bolus versus continuous infusion of Piperacillin and Tazobactam on the development of antimicrobial resistance in Pseudomonas aeruginosa. Antimicrob Agents Chemother. 2013; 57(12):5811–9. https://doi.org/10.1128/AAC.00867-13 PMID: 24002098

21. Thalhammer F, Traunmüller F, El Menyawer I, Frass M, Hollenstein UM, Locker GJ, et al. Continuous infusion versus intermittent administration of meropenem in critically ill patients. J Antimicrob Chemother. 1999; 43(4):523–7. https://doi.org/10.1093/jac/43.4.523 PMID: 10360382

22. Burgess SV, Mabasa VH, Chow I, Ensom MHH. Evaluating outcomes of alternative dosing strategies for cefepime: a qualitative systematic review. The Annals of pharmacotherapy. 2015; 49(3):311–22. https://doi.org/10.1177/1060028014564179 PMID: 25575975

23. Lee YR, Miller PD, Alzghari SK, Blanco DD, Hager JD, Kuntz KS. Correction to: Continuous Infusion Versus Intermittent Bolus of Beta-Lactams in Critically Ill Patients with Respiratory Infections: A Systematic Review and Meta-analysis. European journal of drug metabolism and pharmacokinetics. 2018; 43(2):171. https://doi.org/10.1007/s13318-017-0446-6 PMID: 29116616

24. Teo J, Liew Y, Lee W, Kwa AL-H. Prolonged infusion versus intermittent boluses of beta-lactam antibiotics for treatment of acute infections: a meta-analysis. International journal of antimicrobial agents. 2014; 43(5):403–11. https://doi.org/10.1016/j.ijantimicag.2014.01.027 PMID: 24657044

25. Rhodes NJ, Liu J, O’Donnell JN, Dulhunty JM, Abdul-Aziz MH, Berko PY, et al. Prolonged Infusion Piperacillin-Tazobactam Decreases Mortality and Improves Outcomes in Severely Ill Patients: Results of a Systematic Review and Meta-Analysis. Critical care medicine. 2018; 46(2):236–43. https://doi.org/10.1097/CCM.0b013e3181a0054d PMID: 29116995

26. Roberts JA, Webb S, Paterson D, Ho KM, Lipman J. A systematic review on clinical benefits of continuous administration of beta-lactam antibiotics. Critical care medicine. 2009; 37(6):2071–8. https://doi.org/10.1097/CCM.0b013e3181b0654d PMID: 19384201

27. Tamma PD, Putcha N, Suh YD, Van Arendonk KJ, Rinke ML. Does prolonged beta-lactam infusions improve clinical outcomes compared to intermittent infusions? A meta-analysis and systematic review of randomized, controlled trials. BMC infectious diseases. 2011; 11:181. https://doi.org/10.1186/1471-2334-11-181 PMID: 21669619

28. Mah GT, Mabasa VH, Chow I, Ensom MHH. Evaluating outcomes associated with alternative dosing strategies for piperacillin/tazobactam: a qualitative systematic review. The Annals of pharmacotherapy. 2012; 46(2):265–75. https://doi.org/10.1345/aph.1Q378 PMID: 22274145

29. Vardakas KZ, Voulgaris GL, Malarios A, Samonis G, Falagas ME. Prolonged versus short-term intravenous infusion of antipseudomonal beta-lactams for patients with sepsis: a systematic review and meta-analysis of randomised trials. The Lancet Infectious diseases. 2018; 18(1):108–20. https://doi.org/10.1016/S1473-3099(17)30615-1 PMID: 29102324

30. Yang H, Cui X, Ma Z, Liu L. Evaluation Outcomes Associated with Alternative Dosing Strategies for Piperacillin/Tazobactam: A Systematic Review and Meta-Analysis. Journal of pharmacy & pharmaceutical sciences: a publication of the Canadian Society for Pharmaceutical Sciences, Societe canadienne des sciences pharmaceutiques. 2016; 19(2):274–89.

31. Yang H, Zhang C, Zhou Q, Wang Y, Chen L. Clinical outcomes with alternative dosing strategies for piperacillin/tazobactam: a systematic review and meta-analysis. PloS one. 2015; 10(1):e0116769. https://doi.org/10.1371/journal.pone.0116769 PMID: 25575030
32. Yu Z, Pang X, Wu X, Shan C, Jiang S. Clinical outcomes of prolonged infusion (extended infusion or continuous infusion) versus intermittent bolus of meropenem in severe infection: A meta-analysis. PloS one. 2018; 13(7):e0201667. https://doi.org/10.1371/journal.pone.0201667 PMID: 30059536

33. Yusuf E, Spapen H, Pierard D. Prolonged vs intermittent infusion of piperacillin/tazobactam in critically ill patients: a narrative and systematic review. Journal of critical care. 2014; 29(6):1089–95. https://doi.org/10.1016/j.jcrc.2014.07.033 PMID: 25179412

34. Perrott J, Mabasa VH, Ensom MHH. Comparing outcomes of meropenem administration strategies based on pharmacokinetic and pharmacodynamic principles: a qualitative systematic review. The Annals of pharmacotherapy. 2010; 44(3):557–64. https://doi.org/10.1345/aph.1M339 PMID: 20124468

35. Walker MC, Lam WM, Manasco KB. Continuous and extended infusions of beta-lactam antibiotics in the pediatric population. Ann Pharmacother. 2012; 46(11):1537–46. https://doi.org/10.1345/aph.1R216 PMID: 23115223

36. Falagas ME, Tansarli GS, Ikawa K, Vardakas KZ. Clinical outcomes with extended or continuous versus short-term intravenous infusion of carbapenems and piperacillin/tazobactam: a systematic review and meta-analysis. Clin Infect Dis. 2013; 56(2):272–82. https://doi.org/10.1093/cid/cis587 PMID: 23074314

37. Pollock M FR, Becker LA, Pieper D, Hartling L. Chapter V: Overviews of Reviews. In: Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA (editors). Cochrane Handbook for Systematic Reviews of Interventions version 6.1 (updated September 2020). Cochrane, 2020. www.training.cochrane.org/handbook.

38. Moher D, Shamseer L, Clarke M, Ghersi D, Liberati A, Petticrew M, et al. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement. Syst Rev. 2015; 4:1. https://doi.org/10.1186/s40814-015-0023-0 PMID: 25554246

39. Shamseer L, Moher D, Clarke M, Ghersi D, Liberati A, Petticrew M, et al. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015: elaboration and explanation. BMJ. 2015; 350:g6747. https://doi.org/10.1136/bmj.g6747 PMID: 25555955

40. Bougioukas KI, Liakos A, Tsapas A, Ntzani E, Haidich AB. Preferred reporting items for overviews of reviews. Biomed Research International. 2016; 2016: 1–8. https://doi.org/10.1155/2016/6799768

41. McGowan J, Sampson M, Salzwedel DM, Cogo E, Foerster V, Lefebvre C. PRESS Peer Review of Electronic Search Strategies: 2015 Guideline Statement. Journal of clinical epidemiology. 2016; 75:40–6. https://doi.org/10.1016/j.jclinepi.2016.01.021 PMID: 27005575

42. CADTH. Grey Matters: a practical tool for searching health-related grey literature 2014.

43. Shea BJ, Reeves BC, Wells G, Thuku M, Hamel C, Moran J, et al. AMSTAR 2: a critical appraisal tool for systematic reviews that include randomised or non-randomised studies of healthcare interventions, or both. BMJ. 2017; 358:j4006. https://doi.org/10.1136/bmj.j4006 PMID: 28935701

44. Whiting P, Savovic J, Higgins JP, Caldwell DM, Reeves BC, Shea B, et al. ROBIS: A new tool to assess risk of bias in systematic reviews was developed. Journal of clinical epidemiology. 2016; 69:225–34. https://doi.org/10.1016/j.jclinepi.2015.06.005 PMID: 26092286

45. Pieper D, Antoine SL, Mathes T, Neugebauer EA, Eikermann M. Systematic review finds overlapping reviews were not mentioned in every other overview. Journal of clinical epidemiology. 2014; 67(4):368–75. https://doi.org/10.1016/j.jclinepi.2013.11.007 PMID: 24581293

46. Pérez-Bracigliione;GuzmanfiguÌ;Urrutia, editor Graphical representation of overlap degree of primary studies in systematic reviews included in overviews. Cochrane Santiago Colloquium 2019; 2019; Santiago.

47. Chant C, Leung A, Friedrich JO. Optimal dosing of antibiotics in critically ill patients by using continuous/extended infusions: a systematic review and meta-analysis. Critical care (London, England). 2013; 17(6):R279. https://doi.org/10.1186/cc13134 PMID: 24289230

48. Hassan F, Abdul AN, Hassan Y, Abu HH, Abdul Wahab NS. Do prolonged infusions of beta lactams improve clinical cure? A meta analysis. International Journal of Pharmaceutical Sciences Review and Research. 2013; 23(2):356–61.

49. Korbila IP, Tansarli GS, Karageorgopoulos DE, Vardakas KZ, Falagas ME. Extended or continuous versus short-term intravenous infusion of cephalosporins: a meta-analysis. Expert review of anti-infective therapy. 2013; 11(6):585–95. https://doi.org/10.1586/eri.13.44 PMID: 23750730

50. Lai A, Jaudre P, El-Soh AA. Prolonged versus Intermittent Infusion of beta-Lactams for the Treatment of Nosocomial Pneumonia: A Meta-Analysis. Infection & Chemotherapy. 2016; 48(2):81–90. https://doi.org/10.3947/ic.2016.48.2.81 PMID: 27433378
51. Lux LJ, Posey RE, Daniels LS, Henke DC, Durham C, Jonas DE, et al. Pharmacokinetic/Pharmacodynamic Measures for Guiding Antibiotic Treatment for Hospital-Acquired Pneumonia. 2014.

52. Roberts JA, Paratz J, Paratz E, Krueger WA, Lipman J. Continuous infusion of beta-lactam antibiotics in severe infections: a review of its role. Int J Antimicrob Agents. 2007; 30(1):11–8. https://doi.org/10.1016/j.ijantimicag.2007.02.002 PMID: 17442541

53. Acosta Garcia H, Victoria Gil-Navarro M, Cotrina Luque J, Cisneros Herreros JM, Lepe Jimenez JA, Bautista Paloma J. [Piperacillin-tazobactam in continuous or expanded perfusion vs intermittent perfusion]. Farmacia hospitalaria: organo oficial de expresion cientifica de la Sociedad Espanola de Farmacia Hospitalaria. 2012; 36(5):424–9. https://doi.org/10.1016/j.farma.2011.06.013 PMID: 22871367

54. Lee YR, Miller PD, Alzghari SK, Blanco DD, Hager JD, Kuntz KS. Continuous Infusion Versus Intermittent Bolus of Beta-Lactams in Critically Ill Patients with Respiratory Infections: A Systematic Review and Meta-analysis. Eur J Drug Metab Pharmacokinet. 2018; 43(2):155–70. https://doi.org/10.1007/s13318-017-0439-5 PMID: 29027128

55. Chytra I, Stepan M, Benes J, Pelnar P, Zidkova A, Bergerova T, et al. Clinical and microbiological efficacy of continuous versus intermittent application of meropenem in critically ill patients: a randomized open-label controlled trial. Crit Care. 2012; 16(3):R113. https://doi.org/10.1186/cc11405 PMID: 22742765

56. Shabaan AE, Nour I, Elsayed Eldegla H, Nasef N, Shouman B, Abdel-Hady H. Conventional Versus Prolonged Infusion of Meropenem in Neonates With Gram-negative Late-onset Sepsis: A Randomized Controlled Trial. Pediatr Infect Dis J. 2017; 36(4):358–63. https://doi.org/10.1097/INF.0000000000001443 PMID: 27918392

57. Wang Z, Shan T, Liu Y, Ding S, Li C, Zhai Q, et al. [Comparison of 3-hour and 30-minute infusion regimens for meropenem in patients with hospital acquired pneumonia in intensive care unit: a randomized controlled clinical trial]. Zhonghua wei zhong bing ji jiu yi xue. 2014; 26(9):644–9. https://doi.org/10.3760/cma.j.issn.2095-4352.2014.09.008 PMID: 25230866

58. Zhao HY, Gu J, Lyu J, Liu D, Wang YT, Liu F, et al. Pharmacokinetic and Pharmacodynamic Efficacies of Continuous versus Intermittent Administration of Meropenem in Patients with Severe Sepsis and Septic Shock: A Prospective Randomized Pilot Study. Chin Med J (Engl). 2017; 130(10):1139–45. https://doi.org/10.4103/0366-6999.205859 PMID: 28485312

59. Centre for Reviews and D. Clinical outcomes with extended or continuous versus short-term intravenous infusion of carbapenems and piperacillin/tazobactam: a systematic review and meta-analysis (Provisional abstract). Database of Abstracts of Reviews of Effects. 2015(2).

60. Lau WK, Mercer D, Itani KM, Nicolau DP, Kuti JL, Mansfield D, et al. Randomized, open-label, comparative study of piperacillin-tazobactam administered by continuous infusion versus intermittent infusion for treatment of hospitalized patients with complicated intra-abdominal infection. Antimicrob Agents Chemother. 2006; 50(11):3556–61. https://doi.org/10.1128/AAC.00329-06 PMID: 16940077

61. Grant EM, Kuti JL, Nicolau DP, Nightingale C, Quintiliani R. Clinical efficacy and pharmacoconomics of a continuous-infusion piperacillin-tazobactam program in a large community teaching hospital. Pharmacotherapy. 2002; 22(4):471–83. https://doi.org/10.1592/phco.22.7.471.33665 PMID: 11939682

62. Lagast H, Meunier-Carpentier F, Klastersky J. Treatment of gram-negative bacillary septicaemia with cefoperazone. European journal of clinical microbiology. 1983; 2(6):554–8. https://doi.org/10.1007/BF02016564 PMID: 666761

63. Glasziou P, Altman DG, Bossuyt P, Boutron I, Clarke M, Julious S, et al. Reducing waste from incomplete or unusable reports of biomedical research. Lancet. 2014; 383(9913):267–76. https://doi.org/10.1016/S0140-6736(13)62228-X PMID: 24411647

64. Ioannidis JP, Greenland S, Hlatky MA, Khoury MJ, Macleod MR, Moher D, et al. Increasing value and reducing waste in research design, conduct, and analysis. Lancet. 2014; 383(9912):166–75. https://doi.org/10.1016/S0140-6736(13)62227-8 PMID: 24411645